Martin B.
- Country
- Germany
- Department
- Medizinische Klinik III
Research Overview
- A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
- Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 83 of 284 partner sites.
Specializations
Lymphoma Specialization
This investigator demonstrates extensive expertise in treating various forms of B-cell lymphomas, with particular focus on aggressive lymphoma variants. Their research encompasses both rare and common lymphoma subtypes, including primary CNS lymphoma and diffuse large B-cell lymphoma (DLBCL).
- Primary CNS Lymphoma
- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Hodgkin Lymphoma
Treatment Approaches
The investigator specializes in developing innovative therapeutic strategies, including high-dose chemotherapy protocols and stem cell transplantation. Their work involves evaluating novel drug combinations and treatment regimens for various lymphoma subtypes.
- Autologous Stem Cell Transplantation
- Combination Chemotherapy
- Targeted Therapies
- Immunotherapy Approaches
Patient Population Focus
The investigator has significant experience in treating elderly lymphoma patients and developing age-adjusted treatment protocols. Their research addresses specific needs of different age groups and risk categories in lymphoma treatment.
- Elderly Patient Care
- Advanced Stage Disease
- High-Risk Populations
- Previously Untreated Patients
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.